Clinical Trial Update: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2a trial of BAX69 with standard therapies vs. standard of care in metastatic colorectal cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-FU/leucovorin (5-fluorouracil/leucovorin)
• BAX69
• Panitumumab (panitumumab)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-03-19